pravibismane topical (MBN-101) / Microbion - LARVOL DELTA

Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients (clinicaltrials.gov) - P2 | N=47 | Completed | Sponsor: Microbion Corporation | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease

Topical pravibismane as adjunctive therapy for moderate or severe diabetic foot infections: A phase 1b randomized, multicenter, double-blind, placebo-controlled trial. (PubMed, Int Wound J) - P1b/2a | "There were no treatment emergent or serious adverse events related to study drug. The initial findings indicate that topical pravibismane was safe and potentially effective treatment for improving recovery from infected chronic ulcers by reducing ulcer size and facilitating wound healing in infected DFUs (ClinicalTrials.gov Identifier NCT02723539)."

Clinical • Journal • P1 data • Infectious Disease

Microbion's Pravibismane Granted Second FDA Orphan Drug Designation for the Treatment of Non-tuberculous Mycobacterial (NTM) Infections (Canada Newswire) - "Microbion Corporation today announced that the company has been granted a second orphan drug designation for its lead drug candidate, pravibismane, for the treatment of non-tuberculous mycobacterial (NTM) infections. NTM infections are most commonly found in the lungs; however, skin and soft tissue, indwelling medical devices, lymph nodes, and blood can also harbor NTM infections."

Orphan drug • Infectious Disease • Nontuberculous Mycobacterial Disease

Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate/Severe DFI Patients (clinicaltrials.gov) - P2 | N=54 | Recruiting | Sponsor: Microbion Corporation | Active, not recruiting ➔ Recruiting

Enrollment open • Infectious Disease

Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate/Severe DFI Patients (clinicaltrials.gov) - P2 | N=54 | Active, not recruiting | Sponsor: Microbion Corporation | Trial completion date: Jul 2023 ➔ Jan 2024 | Trial primary completion date: Mar 2023 ➔ Sep 2023

Trial completion date • Trial primary completion date • Infectious Disease

Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate/Severe DFI Patients (clinicaltrials.gov) - P2 | N=54 | Active, not recruiting | Sponsor: Microbion Corporation | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease

Multi-center Study to Assess Safety, Tolerability and Efficacy of MBN-101 in Patients With Moderate/Severe DFI (clinicaltrials.gov) - P2 | N=54 | Recruiting | Sponsor: Microbion Corporation | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2022 ➔ Jun 2022

Enrollment open • Trial initiation date • Infectious Disease